FOLH1 and prostate carcinoma: To further enhance the therapeutic efficiency, Zhen et al. developed PSMA aptamer-conjugated cationic liposomes to efficiently and flexibly introduce therapeutic clustered regularly interspaced short palindromic repeats/ CRISPR-associated protein 9 (CRISPR/Cas9) into prostate cancer cells [162].